Last $0.50 USD
Change Today 0.00 / 0.00%
Volume 0.0
BZNE On Other Exchanges
Symbol
Exchange
OTC BB
As of 8:10 PM 06/14/13 All times are local (Market data is delayed by at least 15 minutes).

biozone pharmaceuticals inc (BZNE) Snapshot

Open
$0.50
Previous Close
$0.50
Day High
$0.50
Day Low
$0.50
52 Week High
01/2/13 - $3.75
52 Week Low
05/3/13 - $0.21
Market Cap
31.7M
Average Volume 10 Days
270.3
EPS TTM
--
Shares Outstanding
63.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOZONE PHARMACEUTICALS INC (BZNE)

Related News

No related news articles were found.

biozone pharmaceuticals inc (BZNE) Related Businessweek News

No Related Businessweek News Found

biozone pharmaceuticals inc (BZNE) Details

Biozone Pharmaceuticals, Inc., through its subsidiaries, engages in developing and manufacturing over the counter (OTC) drug products, and cosmetic and beauty products on behalf of third parties in the United States and internationally. Its OTC products include hair conditioners and shampoos for treatment of eczema and psoriasis; external analgesics; skin protectants; anti-fungal products; topical anesthetics; nasal sprays; wound care products; acne products; cough and cold products; anti-itch products; and skin lightening products. The company’s cosmetic and beauty products comprise AHA and Beta Hydroxy products, instant firming serums, anti-aging products, body lotions, eye creams, moisture creams and lotions, facial scrubs, and facial masks. It also manufactures and sells dietary supplements, including vitamins, minerals, and herbal remedies. In addition, the company manufactures and sells two proprietary brands of skin care products, Glyderm and Baker Cummins, to national wholesalers; and e-commerce retailers, such as Drugstore.com and Skinstore.com. Further, it sells raw materials containing QuSomes, its proprietary delivery agents to the manufacturers of OTC drugs and cosmetics in the United States, as well as licenses the right to use QuSomes to OTC manufacturers. Biozone Pharmaceuticals, Inc. is headquartered in Englewood Cliffs, New Jersey.

69 Employees
Last Reported Date: 04/1/13

biozone pharmaceuticals inc (BZNE) Top Compensated Officers

Chief Executive Officer, Chief Financial Offi...
Total Annual Compensation: $550.0K
Co-Founder, President, Chief Scientific Offic...
Total Annual Compensation: $176.1K
Chief Strategy Officer
Total Annual Compensation: $105.0K
Compensation as of Fiscal Year 2012.

biozone pharmaceuticals inc (BZNE) Key Developments

Biozone Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt

Biozone Pharmaceuticals, Inc. filed its 10-K on Apr 01, 2013 for the period ending Dec 31, 2012. In this report its auditor, Paritz & Company, P.A., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Biozone Pharmaceuticals, Inc. announced delayed annual 10-K filing

On 03/18/2013, Biozone Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Biozone Pharmaceuticals, Inc. announced delayed 10-Q filing

On 05/15/2012, Biozone Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BZNE:US $0.50 USD 0.00

BZNE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Perrigo Co $120.09 USD -1.07
View Industry Companies
 

Industry Analysis

BZNE

Industry Average

Valuation BZNE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOZONE PHARMACEUTICALS INC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.